Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study

BACKGROUND: Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population. Little i...

Descripción completa

Detalles Bibliográficos
Autores principales: Annic, Josselin, Babey, Hélène, Corre, Romain, Descourt, Renaud, Quéré, Gilles, Renaud, Emmanuelle, Lambert, Mickaël, Le Noac'h, Pierre, Dhamelincourt, Estelle, Nguyen, Jessica, Vu, Alicia, Bourbonne, Vincent, Robinet, Gilles, Geier, Margaux
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939142/
https://www.ncbi.nlm.nih.gov/pubmed/36000584
http://dx.doi.org/10.1002/cam4.5143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939142/
https://www.ncbi.nlm.nih.gov/pubmed/36000584
http://dx.doi.org/10.1002/cam4.5143

Ejemplares similares